Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Nationwide Children's Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05843253CT.gov Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Glioma, H3 G34 Mutant
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ribociclib (this asset) | Nationwide Children's Hospital | P2 | CCC · 53 |
| Everolimus | Nationwide Children's Hospital | P2 | CCC |
| Pegargiminase | Sabine Mueller, MD, PhD | P1/2 | CCC |
| Avutometinib | Institute of Cancer Research, United Kingdom | P1/2 | CC |
| Defactinib | Institute of Cancer Research, United Kingdom | P1/2 | CC |
| Nivolumab | Andrew P. Groves | P1 | CC |
| Vipivotide Tetraxetan | Memorial Sloan Kettering Cancer Center | P1 | CC |
| Azacitidine | Andrew P. Groves | P1 | CC |
| Amivantamab-Vmjw | Institute of Cancer Research, United Kingdom | P1 | CC |
+1 more in the Diffuse Glioma, H3 G34 Mutant cohort
Other indications for Ribociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 73 |
| Breast Cancer | — | P4 | BB · 70 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ribociclib in Diffuse Glioma, H3 G34 Mutant. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ribociclib-diffuse-glioma-h3-g34-mutant
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →